TP53 codon 72 polymorphism in classic, endemic and epidemic kaposi's sarcoma in African and caucasian patients

Oncology

Volumn 77, Issue 5, 2009, Pages 328-334

  Tornesello, Maria Lina ^a   Biryahwaho, Bennon ^b   Downing, Robert ^b   Hatzakis, Angelo ^c   Alessi, Elvio ^d   Cusini, Marco ^d   Ruocco, Vincenzo ^e   Katongole Mbidde, Edward ^b   Buonaguro, Luigi ^a   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF MILAN   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cancer risk; Genetic susceptibility; Kaposi's sarcoma; TP53 polymorphism

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CAUCASIAN; CODON; ENDEMIC DISEASE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN P53 GENE; SKIN DEFECT; STATISTICAL SIGNIFICANCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CODON; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SARCOMA, KAPOSI;

EID: 70450189678     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260905     Document Type: Article

References (59)

1. Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Biberfeld P: KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development. Infect Agent Cancer 2007; 2: 4.
2. Kaposi M: Idiopathisches multiples pigment sarcoma der Haut. Arch Dermatol Syphil 1872; 4: 265-267.
3. Hutt MS, Burkitt D: Geographical distribution of cancer in East Africa: a new clinicopathological approach. Br Med J 1965;2:719-722.
4. Biggar RJ, Horm J, Lubin JH, Goedert JJ, Greene MH, Fraumeni JF Jr: Cancer trends in a population at risk of acquired immunodeficiency syndrome. J Natl Cancer Inst 1985; 74: 793-797.
5. Penn I: Kaposi's sarcoma in immunosuppressed patients. J Clin Lab Immunol 1983; 12: 1-10.
6. Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G: Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65: 25-28.
7. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
8. Mbulaiteye SM, Engels EA: Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer 2006; 119: 2685-2691.
9. Whitby D, Marshall VA, Bagni RK, Miley WJ, McCloud TG, Hines-Boykin R, Goedert JJ, Conde BA, Nagashima K, Mikovits J, Dittmer DP, Newman DJ: Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer 2007; 120: 321-328.
10. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000; 408: 307-310.
11. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-2908.
12. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987; 7: 961-963.
13. Pietsch EC, Humbey O, Murphy ME: Polymorphisms in the p53 pathway. Oncogene 2006; 25: 1602-1611.
14. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-234.
15. Shen H, Solari A, Wang X, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wei Q: P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep 2004; 11: 1115-1120.
16. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL: The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11: 1684-1688.
17. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C: Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003; 9: 4860-4864.
18. Buyru N, Tigli H, Dalay N: P53 codon 72 polymorphism in breast cancer. Oncol Rep 2003; 10: 711-714.
19. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman MT, Eisenberg BS, Friedman E: The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 2005; 92: 1144-1148.
20. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K: p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 2000; 60: 2753-2755.
21. Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA: P53 codon 72 polymorphism as a risk factor in the development of HPVassociated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med 2000; 5: 405-409.
22. Bastiaens MT, Struyk L, Tjong-A-Hung SP, Gruis N, ter Huurne J, Westendorp RG, Vermeer BJ, Bavinck JN, ter Schegget J: Cutaneous squamous cell carcinoma and p53 codon polymorphism: a need for screening? Mol Carcinog 2001; 30: 56-61.
23. Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei Q: p53 codon Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 2003; 121: 1510-1514.
24. de Oliveira WR, Rady PL, Grady J, Hughes TK, Neto CF, Rivitti EA, Tyring SK: Association of p53 arginine polymorphism with skin cancer. Int J Dermatol 2004; 43: 489-493.
25. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR: p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002; 94: 681-690.
26. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA: p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002; 179: 175-183.
27. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM: Association of codon polymorphism of p53 with lower prostate cancer risk. Prostate 2001; 49: 263-266.
28. Sourvinos G, Rizos E, Spandidos DA: p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol 2001; 37: 572-578.
29. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS: Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 2004; 210: 151-157.
30. Tiwawech D, Srivatanakul P, Karaluk A, Ishida T: The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer Lett 2003; 198: 69-75.
31. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, Okugi H, Koike H, Ono Y, Ito K, Kurokawa K, Yamanaka H: A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003; 10: 430-435.
32. Chen YC, Xu L, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Chaor SC, Lee JY, Christiani DC: Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J Environ Sci Health A Tox Hazard Subst Environ Eng 2003; 38: 201-211.
33. Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T: p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 2003; 189: 77-83. (Pubitemid 35351522)
34. Wang YC, Chen CY, Chen SK, Chang YY, Lin P: p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999; 5: 129-134. (Pubitemid 29045185)
35. Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
36. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328-3337.
37. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT: TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005; 26: 1770-1773.
38. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y: p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 7328-7333.
39. Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G: Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65: 25-28.
40. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
41. Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G: Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65: 25-28.
42. Tornesello ML, Waddell KM, Duraturo ML, Biryahwaho B, Downing R, Lucas SB, Giani U, Buonaguro L, Buonaguro FM: TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detect Prev 2005; 29: 501-508.
43. Tornesello ML, Duraturo ML, Guida V, Losito S, Botti G, Pilotti S, Stefanon B, De Palo G, Buonaguro L, Buonaguro FM: Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma. Cancer Lett 2008; 269: 159-164.
44. Albert J, Fenyo EM: Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol 1990; 28: 1560-1564.
45. Higuchi R: Simple and rapid preparation of samples for PCR; in Erlich H (ed): PCR Technology: Principles and Applications for DNA Amplification. New York, Stockton Press, 1989, pp 31-38.
46. Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G: Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65: 25-28.
47. Buonaguro FM, Giraldo G, Nakamura Y, Vecchione R, Alessi E, Finzi AF, Safai B, Mueller N, Hatzakis A, Owili DM: Genetic mechanisms in Kaposi's sarcoma pathogenesis. (abstract No. WA1102). 7th International Conference on AIDS, Florence, June 1991.
48. Quinn AG, Sikkink S, Rees JL: Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 1994; 54: 4756-4759.
49. Puente XS, Velasco G, Gutierrez-Fernandez A, Bertranpetit J, King MC, Lopez-Otin C: Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics 2006; 7: 15.
50. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L: Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 266-270.
51. Ko LJ, Prives C: p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
52. Dobner T, Horikoshi N, Rubenwolf S, Shenk T: Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 1996; 272: 1470-1473.
53. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
54. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-79.
55. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092-1100.
56. Dumont P, Leu JI, Della PA, III, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-365.
57. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ: p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-894.
58. Si H, Robertson ES: Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol 2006; 80: 697-709.
59. Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.